(Q36648720)

15 August 2017

Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy (English)

1 reference

15 August 2017

1 reference

1 reference

1

I Ray-Coquard

0 references

Axel Le Cesne

7

object named as

A Le Cesne

0 references

Jean-Yves Blay

10

object named as

J Y Blay

0 references

author name string

C Borg

2

1 reference

15 August 2017

Th Bachelot

3

1 reference

15 August 2017

C Sebban

4

1 reference

15 August 2017

I Philip

5

1 reference

15 August 2017

G Clapisson

6

1 reference

15 August 2017

P Biron

8

1 reference

15 August 2017

F Chauvin

9

1 reference

15 August 2017

ELYPSE study group

11

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

88

1 reference

15 August 2017

2

1 reference

15 August 2017

181-186

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6600724

15 August 2017

0 references

cites work

Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377052

A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377052

Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377052

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377052

Granulocyte growth factors: achieving a consensus

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377052

Infection in cancer patients. A continuing association

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377052

A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377052

Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377052

LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377052

Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377052

Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377052

Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377052

Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377052

A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377052

Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncolo

28 June 2018

1 reference

12 December 2020

Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy

1 reference

12 December 2020

Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol

1 reference

12 December 2020

American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines

1 reference

12 December 2020

Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6600724

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

12610500

1 reference